Teva bullish ahead of 2-step biosimilar attack on AbbVie's blockbuster Humira
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
A determined FDA takes down Teva's blockbuster | Evaluate
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva to cut 14,000 jobs | Business | Chemistry World
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ELYBYTG4QZMUJPXRYDKAVNSTAI.jpg "New branded drugs helping Teva Pharm move closer to growth | Reuters")
New branded drugs helping Teva Pharm move closer to growth | Reuters
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva agrees to buy Allergan's generics distribution unit
In opioid case, NY wants to probe Teva's control of Teva USA
Sex, drugs, and sharing trade secrets
Why Teva Pharmaceutical Is Substantially More (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Industries Ltd. | BioWorld
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Generics distributor Anda, Inc. has a new owner: Teva Pharma
Teva buys Allergan: 3 reasons why it's a blockbuster deal | Fortune
Report: Teva Suffers Migraine Over Express Scripts Drug Exclusion - Pharmaceutical Processing World
Teva Pharmaceutical to ax 14,000 workers worldwide - CBS News
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
Teva seeks blockbuster drug to succeed Copaxone - Globes
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Silver Spring-based United Therapeutics settles patent dispute over Remodulin generic with Teva Pharmaceuticals - Washington Business Journal
